By Fineline Cube 
On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration with IRE EliT, a leading international company in radioisotope technology. The partnership will bring IRE EliT’s pharmaceutical-grade Germanium-68/Gallium-68 (68Ge/68Ga) generator technology to the Chinese market.
Exclusive Distribution Agreement
Grand Pharma’s wholly-owned subsidiary, Chengdu Purevalley Medical Technology Co., Ltd., has signed an exclusive China distribution agreement. This positions Chengdu Purevalley as the sole supplier and service provider for IRE EliT’s 68Ge/68Ga generators in China.
Collaboration Goals
The collaboration aims to leverage the strengths of both companies in R&D, manufacturing, market access, and commercialization. By introducing IRE EliT’s globally recognized generator technology and regulatory expertise, the partnership seeks to promote the widespread application of this technology in China.
Benefits for the Chinese Market
- Stable Supply of High-Tech Products: Ensuring Chinese medical institutions have a continuous supply of 68Ge/68Ga generators that meet international standards, supporting 68Ga PET imaging operations.
- Improved Nuclear Medicine Diagnosis: Promoting the adoption and standardized use of 68Ga-labeled PET imaging technology to enable earlier and more accurate diagnoses for patients.
- Empowering Precision Medicine: Providing a foundation for personalized treatment strategies, enhancing treatment outcomes, and optimizing healthcare resource allocation.
- Localized Ecosystem Potential: Exploring possibilities for a localized supply chain based on regulatory requirements to strengthen the resilience and security of the industrial chain.-Fineline Info & Tech